CClinicalTrials.gg
RecruitingNCT07218237MINDBPUpdated Sep 16, 2026

Mindfulness and Wearable Biosensors to Prevent Hypertensive Disorders of Pregnancy

An interventional study of Mindfulness training and Garmin Vivoactive 4 watch in Preeclampsia, sponsored by Medical College of Wisconsin. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The MINDBP study will enroll 90 pregnant women at risk for HDP across two sites (MCW and Brown) and randomize them to: (1) mindfulness training (MT) plus wearable biosensors, (2) MT alone, or (3) routine prenatal care. MT participants will receive 8 weekly phone-based MT sessions plus two booster sessions at 1 and 2 months post-intervention. The primary outcome is study feasibility.

Read the detailed description

The MINDBP study will enroll 90 pregnant women at risk for HDP across two sites (MCW and Brown) and randomize them to: (1) MT + wearable biosensors, (2) MT alone, or (3) routine prenatal care. MT participants will receive 8 weekly phone-based MT sessions plus two booster sessions at 1 and 2 months post-intervention. All participants will wear Garmin Vivoactive 4 watches. Blood pressure, heart rate, heart rate variability, perceived stress, and pregnancy-related anxiety will be assessed at baseline (≤16 weeks), post-intervention (\~24 weeks), and after each booster (\~28 and 32 weeks). Feasibility, fidelity, and acceptability outcomes will be assessed after each post-intervention

02

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • Hypertensive disorders of pregnancy
  • Mindfulness
  • Biofeedback
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pregnant patients at gestational age \<= 16 weeks
  • Live, non-anomalous gestation
  • Normotensive at enrollment
  • Meet criteria consistent with 'moderate' to 'high' risk for preeclampsia based on ACOG/USPSTF guidelines for low-dose aspirin administration to prevent hypertensive disorders of pregnancy

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Chronic (pregestational hypertension)
  • Inability of unwillingness to provide informed consent
  • Active suicidality or psychosis
  • Ongoing mind-body practice (e.g., yoga, meditation, mindfulness >= once per week)
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    MT + Biofeedback

    Mindfulness training plus self-monitoring with access to data from wearable biosensor

    Behavioral: Mindfulness training · Behavioral: Garmin Vivoactive 4 watch

  • Experimental
    MT

    Mindfulness training (no access to wearable biosensor data)

    Behavioral: Mindfulness training

  • No intervention
    Control

    Routine prenatal care alone

Interventions

  • BehavioralMindfulness training

    Mindfulness training with trained instructors

  • BehavioralGarmin Vivoactive 4 watch

    Biofeedback with a wearable biosensor that continuously monitors heart rate variability and generates stress scores.

05

What researchers measure

Primary outcomes

  1. Feasibility of multisite RCT

    Assess study feasibility as measured by retention rate

    Time frame: 3 years

Secondary outcomes

  1. Acceptability of MINDBP intervention

    Assess intervention acceptability using Theoretical Framework of Acceptability Questionns (TFAQ). The TFAQ include 8 Likert-scale items which are averaged to provide an overall score from 1-5, with 5 indicating higher acceptability.

    Time frame: Collected at the 3 study visits: 1 week, 1 month, and 2 months after completion of 8-week mindfulness training intervention.

  2. Home blood pressure

    Average systolic and diastolic blood pressure measured using home blood pressure monitoring

    Time frame: Daily blood pressure measurements for 6 weeks throughout the study

  3. Heart rate variability

    Average daily stress score based on heart rate variability from biosensor watch

    Time frame: Up to 34 weeks

  4. Perceived stress

    Self-reported perceived stress using the Perceived Stress Scale, which is scored from 0-40, with higher scores indicating higher perceived stress.

    Time frame: Measured at baseline and 2, 3, and 4 months after consent.

  5. Pregnancy-related anxiety

    Self-reported pregnancy-related anxiety using the PRAQ-R2, which is cored from 0-40, with higher scores indicating higher anxiety.

    Time frame: Measured at baseline and 2, 3, and 4 months after consent.

06

Study locations

2 of 2 sites recruiting
  • Brown University
    Providence, Rhode Island 02904, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Data collected in the study will include information collected from participants during pregnancy and up to 6 weeks postpartum. Variables will include demographic information, participant-reported survey data, wearable biosensor data, and maternal blood pressure from n=90 participants. All data will be de-identified prior to data sharing.

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07218237
Lead sponsor
Medical College of Wisconsin
Responsible party
Anna Palatnik, MD (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Oct 20, 2025
Start date
Apr 1, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Anna Palatnik, MD
Contact
apalatnik@mcw.edu
14148056627
Alyssa Hernandez, DO
Contact
alyhernandez@mcw.edu
4149552781
Anna Palatnik, MD
principal investigator · Medical College of Wisconsin
Margaret Bublitz, PhD
principal investigator · Brown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion